Improving drug delivery in paediatric medicine

被引:42
作者
Krause J. [1 ]
Breitkreutz J. [1 ,2 ]
机构
[1] Heinrich-Heine-University Düsseldorf, Institute of Pharmaceutics and Biopharmaceutics, Düsseldorf
[2] Heinrich-Heine-University Düsseldorf, Institute of Pharmaceutics and Biopharmaceutics, 40225 Düsseldorf
关键词
Adolescents; Aerosols; Buccal; Children; Controlled release drugs; Drug delivery systems; Enema preparations; European Medicines Agency; Excipients; Granules; Infusion; Inhalation; Inhaler devices; Intravenous; Legislation; Microparticles; Neonates; Oral; Parenteral;
D O I
10.1007/BF03256681
中图分类号
学科分类号
摘要
A major challenge in drug development is paediatric drug delivery; however, the problems associated with drug administration in this population are manifold. Because of the highly heterogeneous nature of the patient group, ranging from newborns to adolescents, there is a need to use suitable excipients and dosage forms for different age groups and suitable delivery devices for certain formulations. So far, there is a lack of suitable and safe drug formulations for children, especially for the very young and seriously ill. This review provides an overview of current advances in the field of paediatric drug delivery and the challenges that still need to be overcome. With the new EU legislation, which will enforce paediatric clinical trials and drug development, there will be an increased need for more research in to novel paediatric dosage forms. There is also the basic need to further investigate the suitability of dosage forms for different age groups. Current advances in paediatric drug development include interesting new drug delivery concepts such as fast-dissolving drug formulations, including buccal films and wafers, and multiparticulate dosage forms. Parenteral administration is likely to remain the first choice for children in the neonatal period and for emergency cases. Alternative routes of administration also under investigation include transdermal, pulmonary and nasal drug delivery systems. A few products are already available on the market, but others are still under development and will need further investigation and clinical proof. © 2008 Adis Data Information BV. All rights reserved.
引用
收藏
页码:41 / 50
页数:9
相关论文
共 49 条
[1]  
Kearns G.L., Abdel-Rahman S.M., Alander S.W., Et al., Developmental pharmacology-drug disposition, action, and therapy in infants and children, New Engl J Med, 349, pp. 1157-1167, (2003)
[2]  
Rakhmanina N.Y., van den Anker J., Pharmacological research in pediatrics: From neonates to adolescents, Adv Drug Deliv Rev, 58, pp. 4-14, (2006)
[3]  
Note for guidance on clinical investigation of medicinal products in the paediatric population, Clinical investigations of medicinal products in the paediatric population
[4]  
Schirm E., Tobi H., Vries T.W., Et al., Lack of appropriate formulations of medicines for children in the community, Acta Paediatr, 92, pp. 1486-1489, (2003)
[5]  
Breitkreutz J., Wessel T., Boos J., Dosage forms for peroral drug administration to children, Paediatr Perinat Drug Ther, 3, pp. 25-33, (1999)
[6]  
Breitkreutz J., Boos J., Paediatric and geriatric drug delivery, Expert Opin Drug Deliv, 4, 1, pp. 37-45, (2007)
[7]  
MacDonald M.G., Getson P.R., Glasgow A.M., Et al., Propylene glycol: Increased incidence of seizures in low birth weight infants, Pediatrics, 79, 4, pp. 622-625, (1987)
[8]  
Glover M.L., Reed M.D., Propylene glycol: The safe diluent that continues to cause harm, Pharmacotherapy, 16, 4, pp. 690-693, (1996)
[9]  
McCann D., Barrett A., Cooper A., Et al., Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: A randomised, doubleblinded, placebo-controlled trial, Lancet, 370, 9598, pp. 1560-1567, (2007)
[10]  
US Food and Drug Administration, Guidance for industry: Testing of glycerine for diethylene glycol